Purple Biotech AAQS

What does Purple Biotech do? Purple Biotech Ltd. develops pharmaceutical products including NT-219, a small molecule bi-specific inhibitor targeting two key cancer resistance pathways, and CM-24, a monoclonal antibody blocker. The company also owns Consensi, a fixed-dose combination of celecoxib and amlodipine besylate designed for treating osteoarthritis pain and hypertension simultaneously. These products are developed for clinical use in oncology and chronic condition management, with NT-219 and CM-24 focused on cancer treatment and Consensi addressing dual therapeutic needs in musculoskeletal and cardiovascular health. The company generates revenue through the development and potential future commercialization of its drug portfolio. NT-219 and CM-24 are in development for oncology applications, while Consensi is positioned as a fixed-dose combination for osteoarthritis and hypertension. The target market includes healthcare providers and patients requiring treatments for cancer, osteoarthritis, and hypertension, with Consensi offering a dual therapy solution that may appeal to patients managing multiple chronic conditions. Purple Biotech is one of the most popular companies on Eulerpool.